JPWO2020112961A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112961A5 JPWO2020112961A5 JP2021531035A JP2021531035A JPWO2020112961A5 JP WO2020112961 A5 JPWO2020112961 A5 JP WO2020112961A5 JP 2021531035 A JP2021531035 A JP 2021531035A JP 2021531035 A JP2021531035 A JP 2021531035A JP WO2020112961 A5 JPWO2020112961 A5 JP WO2020112961A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- solid solution
- capsule formulation
- nonionic surfactant
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 | |
| US62/773,848 | 2018-11-30 | ||
| PCT/US2019/063547 WO2020112961A1 (en) | 2018-11-30 | 2019-11-27 | Capsule formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510304A JP2022510304A (ja) | 2022-01-26 |
| JPWO2020112961A5 true JPWO2020112961A5 (da) | 2023-03-15 |
| JP7342124B2 JP7342124B2 (ja) | 2023-09-11 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531035A Active JP7342124B2 (ja) | 2018-11-30 | 2019-11-27 | カプセル製剤 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20200170957A1 (da) |
| EP (2) | EP4233850A3 (da) |
| JP (1) | JP7342124B2 (da) |
| KR (1) | KR102586747B1 (da) |
| CN (1) | CN113164403A (da) |
| AR (1) | AR117219A1 (da) |
| AU (1) | AU2019389031B2 (da) |
| BR (1) | BR112021010285A2 (da) |
| CA (1) | CA3120999A1 (da) |
| CL (1) | CL2021001389A1 (da) |
| CY (1) | CY1126079T1 (da) |
| DK (1) | DK3886820T3 (da) |
| ES (1) | ES2943492T3 (da) |
| FI (1) | FI3886820T3 (da) |
| HR (1) | HRP20230551T1 (da) |
| HU (1) | HUE062551T2 (da) |
| IL (1) | IL283450B2 (da) |
| LT (1) | LT3886820T (da) |
| MA (1) | MA54318B1 (da) |
| MD (1) | MD3886820T2 (da) |
| MX (1) | MX2021006242A (da) |
| PL (1) | PL3886820T3 (da) |
| PT (1) | PT3886820T (da) |
| RS (1) | RS64250B1 (da) |
| SG (1) | SG11202105572UA (da) |
| SI (1) | SI3886820T1 (da) |
| TW (1) | TWI827745B (da) |
| WO (1) | WO2020112961A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283450B2 (en) | 2018-11-30 | 2024-06-01 | Chemocentryx Inc | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses |
| WO2023225533A1 (en) * | 2022-05-19 | 2023-11-23 | Dow Global Technologies Llc | Use of peg-based interpolymer complexes for improved solubilization of bcs class ii drugs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| CN101065115A (zh) * | 2004-11-24 | 2007-10-31 | 默克公司 | 取代酰胺的液体和半固体口服药物制剂 |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| EP3078658B1 (en) | 2008-12-22 | 2019-04-10 | ChemoCentryx, Inc. | C5ar antagonists |
| KR101579079B1 (ko) * | 2010-03-10 | 2015-12-21 | 애브비 바하마스 리미티드 | 고체 조성물 |
| PL2585064T3 (pl) * | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | Antagoniści C5AR |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| KR20200015830A (ko) | 2014-02-05 | 2020-02-12 | 레크 파마슈티칼스 디.디. | 안드로겐 수용체 길항제의 고체 제약 조성물 |
| DK3200791T3 (da) | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| EP3402486A4 (en) | 2016-01-14 | 2019-08-28 | ChemoCentryx, Inc. | PROCESS FOR TREATING C3 GLOMERULOPATHY |
| KR102395093B1 (ko) | 2016-04-04 | 2022-05-04 | 케모센트릭스, 인크. | 가용성 C5aR 길항제 |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| ES2893769T3 (es) | 2017-04-03 | 2022-02-10 | Inflarx Gmbh | Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a |
| MA50537A (fr) | 2017-10-30 | 2021-04-07 | Chemocentryx Inc | Composés deutérés utilisés comme immunomodulateurs |
| CN111670185A (zh) | 2017-10-31 | 2020-09-15 | 凯莫森特里克斯股份有限公司 | 减少尿sCD163的C5aR抑制剂 |
| BR112020024842A2 (pt) | 2018-06-07 | 2021-03-02 | Chemocentryx, Inc. | dosagem e efeito de antagonista de c5a com vasculite associada a anca |
| IL283450B2 (en) | 2018-11-30 | 2024-06-01 | Chemocentryx Inc | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses |
-
2019
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en active Application Filing
- 2019-11-27 EP EP23160271.5A patent/EP4233850A3/en active Pending
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 CA CA3120999A patent/CA3120999A1/en active Pending
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active IP Right Grant
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4740115B2 (ja) | 置換ピラゾール | |
| TWI338694B (en) | Novel compounds | |
| JP2001520645A (ja) | 新規な化合物 | |
| JP5409010B2 (ja) | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態 | |
| JP2012149093A (ja) | トリアゾロ［４，５−ｄ］ピリミジン化合物の新規な結晶形及び非晶形 | |
| JP2007510620A (ja) | ピラジン誘導体およびその医薬的使用 | |
| TW200920360A (en) | Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | |
| EP1085021A1 (en) | PYRROLO 1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA 2? INHIBITORY EFFECT | |
| CN116637077A (zh) | 包含sGC刺激剂的固体分散体 | |
| JP2003513077A (ja) | カンナビノイドレセプターのアンタゴニストとしての１−ベンジルピラゾール−３−カルボン酸の三環式誘導体 | |
| IL283450B1 (en) | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses | |
| JPH02504033A (ja) | トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体 | |
| JP2018525336A5 (da) | ||
| JPWO2020112961A5 (da) | ||
| TWI358407B (en) | Crystalline base of escitalopram and orodispersibl | |
| US20210078984A1 (en) | Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole | |
| TW201304779A (zh) | 醫藥組合物 | |
| TW200823206A (en) | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine | |
| CA2057338C (en) | Diarylfluoromethane compounds | |
| JP2019522648A (ja) | ２型カンナビノイド受容体に対して親和性を有する［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン誘導体 | |
| TW201006819A (en) | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion | |
| WO2017109772A1 (en) | Amorphous form of selexipag | |
| WO2022028347A1 (zh) | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 | |
| JP2000514096A (ja) | 炭素環式ヌクレオシドヘミスルフェートおよびウイルス感染症の治療におけるその使用 | |
| TW200934774A (en) | Arylmethylidene heterocycles as novel analgesics |